ELVN - Enliven Therapeutics Inc.

ELVN - Enliven Therapeutics Inc.

https://www.enliventherapeutics.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

Enliven Therapeutics, Inc. ( ELVN ) Upgraded to Buy: Here's What You Should Know

Zacks Commentary • 5 days, 23 hours ago • score: 0.34

Enliven Therapeutics, Inc. (ELVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Enliven Posts Loss Beat and Cash Surge

Motley Fool • 1 month ago • score: 0.13

Enliven Therapeutics ( NASDAQ:ELVN ) , a clinical-stage biotechnology company focused on cancer therapies, reported its second quarter 2025 results on August 13, 2025. The release highlighted a net loss per share of $ ( 0.49 ) for Q2 2025 ( GAAP ) , a result that modestly beat the analyst ...

This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - ( ALMS )

Benzinga • 10 months, 2 weeks ago • score: 0.17

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Baird analyst Brian Skorney initiated coverage on Alumis Inc.

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

GlobeNewswire • 11 months, 2 weeks ago • score: 0.20

Updated Phase 1 data presented at ESH-iCMLf 26th Annual John Goldman Conference ...

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia - Enliven Therapeutics ( NASDAQ:ELVN )

Benzinga • 11 months, 2 weeks ago • score: 0.25

Updated Phase 1 data presented at ESH-iCMLf 26th Annual John Goldman Conference Reported cumulative MMR rate of 44% ( 8/18 ) by 24 weeks, with stable or deepening responses between weeks 12 and 24, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

None

52W High

$30.03

52W Low

$13.30

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.03

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-6.28

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

2.44

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

8.89%

Institutions (25–75% balanced)

102.25%

Shares Outstanding

59,236,000

Float

36,320,300

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-1.99

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.25%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.0611

Previous

-0.0646

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025